BACKGROUND & AIMS: Interleukin 6 (IL-6)-mediated signal transducers and activators of transcription 3 (STAT-3) phosphorylation (activation) is aberrantly sustained in cholangiocarcinoma cells resulting in enhanced myeloid cell leukemia 1 (Mcl-1) expression and resistance to apoptosis. Because suppressor of cytokine signaling 3 (SOCS) controls the IL-6/STAT-3 signaling pathway by a classic feedback loop, the aims of this study were to examine SOCS-3 regulation in human cholangiocarcinoma. METHODS: SOCS-3 expression was assessed in human cholangiocarcinoma tissue and the Mz-ChA-1 and CCLP1 human cholangiocarcinoma cell lines. RESULTS: An inverse correlation was observed between phospho-STAT-3 and SOCS-3 protein expression in cholangiocarcinoma. In those cancers failing to express SOCS-3, extensive methylation of the SOCS-3 promoter was demonstrated in tumor but not in paired nontumor tissue. Likewise, methylation of the socs-3 promoter was also identified in 2 cholangiocarcinoma cell lines. Treatment with a demethylating agent, 5-aza-2'-deoxycytidine (DAC), restored IL-6 induction of SOCS-3, terminated the phospho-STAT-3 response, and reduced cellular levels of Mcl-1. Enforced expression of SOCS-3 also reduced IL-6 induction of phospho-STAT-3 and Mcl-1. Either DAC treatment or enforced SOCS-3 expression sensitized the cells to TRAIL-mediated apoptosis. CONCLUSIONS: SOCS-3 epigenetic silencing is responsible for sustained IL-6/STAT-3 signaling and enhanced Mcl-1 expression in cholangiocarcinoma.
BACKGROUND & AIMS:Interleukin 6 (IL-6)-mediated signal transducers and activators of transcription 3 (STAT-3) phosphorylation (activation) is aberrantly sustained in cholangiocarcinoma cells resulting in enhanced myeloid cell leukemia 1 (Mcl-1) expression and resistance to apoptosis. Because suppressor of cytokine signaling 3 (SOCS) controls the IL-6/STAT-3 signaling pathway by a classic feedback loop, the aims of this study were to examine SOCS-3 regulation in humancholangiocarcinoma. METHODS:SOCS-3 expression was assessed in humancholangiocarcinoma tissue and the Mz-ChA-1 and CCLP1humancholangiocarcinoma cell lines. RESULTS: An inverse correlation was observed between phospho-STAT-3 and SOCS-3 protein expression in cholangiocarcinoma. In those cancers failing to express SOCS-3, extensive methylation of the SOCS-3 promoter was demonstrated in tumor but not in paired nontumor tissue. Likewise, methylation of the socs-3 promoter was also identified in 2 cholangiocarcinoma cell lines. Treatment with a demethylating agent, 5-aza-2'-deoxycytidine (DAC), restored IL-6 induction of SOCS-3, terminated the phospho-STAT-3 response, and reduced cellular levels of Mcl-1. Enforced expression of SOCS-3 also reduced IL-6 induction of phospho-STAT-3 and Mcl-1. Either DAC treatment or enforced SOCS-3 expression sensitized the cells to TRAIL-mediated apoptosis. CONCLUSIONS:SOCS-3 epigenetic silencing is responsible for sustained IL-6/STAT-3 signaling and enhanced Mcl-1 expression in cholangiocarcinoma.
Authors: A Knuth; H Gabbert; W Dippold; O Klein; W Sachsse; D Bitter-Suermann; W Prellwitz; K H Meyer zum Büschenfelde Journal: J Hepatol Date: 1985 Impact factor: 25.083
Authors: Y Shimizu; A J Demetris; S M Gollin; P D Storto; H M Bedford; S Altarac; S Iwatsuki; R B Herberman; T L Whiteside Journal: Int J Cancer Date: 1992-09-09 Impact factor: 7.396
Authors: Biao He; Liang You; Kazutsugu Uematsu; Keling Zang; Zhidong Xu; Amie Y Lee; Joseph F Costello; Frank McCormick; David M Jablons Journal: Proc Natl Acad Sci U S A Date: 2003-11-14 Impact factor: 11.205
Authors: Christian D Fingas; Joachim C Mertens; Nataliya Razumilava; Steven F Bronk; Alphonse E Sirica; Gregory J Gores Journal: Liver Int Date: 2011-12-02 Impact factor: 5.828
Authors: Gabriel Frampton; Pietro Invernizzi; Francesca Bernuzzi; Hae Yong Pae; Matthew Quinn; Darijana Horvat; Cheryl Galindo; Li Huang; Matthew McMillin; Brandon Cooper; Lorenza Rimassa; Sharon DeMorrow Journal: Gut Date: 2011-11-07 Impact factor: 23.059